6Q6K

Crystal structure of recombinant human beta-glucocerebrosidase in complex with cyclophellitol activity based probe with Cy5 tag (ME569)

6Q6K の概要

• エントリーDOI: 10.2210/pdb6q6k/pdb
• 分子名称: Glucosylceramidase, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ACETATE ION, ... (7 entities in total)
• 機能のキーワード: hydrolase, retaining beta-glucosidase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 117572.77

構造登録者

Rowland, R.J.,Davies, G.J. (登録日: 2018-12-11, 公開日: 2019-03-27, 最終更新日: 2024-10-23)

主引用文献

Artola, M.,Kuo, C.L.,Lelieveld, L.T.,Rowland, R.J.,van der Marel, G.A.,Codee, J.D.C.,Boot, R.G.,Davies, G.J.,Aerts, J.M.F.G.,Overkleeft, H.S.
Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish.
J.Am.Chem.Soc., 141:4214-4218, 2019

PubMed Abstract: Gaucher disease is caused by inherited deficiency in glucocerebrosidase (GBA, a retaining β-glucosidase), and deficiency in GBA constitutes the largest known genetic risk factor for Parkinson's disease. In the past, animal models of Gaucher disease have been generated by treatment with the mechanism-based GBA inhibitors, conduritol B epoxide (CBE), and cyclophellitol. Both compounds, however, also target other retaining glycosidases, rendering generation and interpretation of such chemical knockout models complicated. Here we demonstrate that cyclophellitol derivatives carrying a bulky hydrophobic substituent at C8 are potent and selective GBA inhibitors and that an unambiguous Gaucher animal model can be readily generated by treatment of zebrafish with these.

PubMed: 30811188
DOI: 10.1021/jacs.9b00056

実験手法

X-RAY DIFFRACTION (1.92 Å)